Literature DB >> 18605983

Transport proteins of the ABC family and multidrug resistance of tumor cells.

A A Stavrovskaya1, T P Stromskaya.   

Abstract

Some new data concerning the role of transport proteins of the ABC family in multidrug resistance (MDR) of human tumor cells, and problems connected with regulation of these proteins are considered. MDR is a complex phenomenon that may be caused simultaneously by several mechanisms functioning in one and the same cell. Among them there may be the alterations of activity of several transport proteins. Activation of these proteins may be associated with alterations of activities of different cell protective systems and of the signal transduction pathways involved in regulation of proliferation, differentiation, and apoptosis. Clinical significance of multifactor MDR is discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18605983     DOI: 10.1134/s0006297908050118

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  36 in total

1.  Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.

Authors:  Hairong Huo; Pellegrino G Magro; E Christy Pietsch; Brijesh B Patel; Kathleen W Scotto
Journal:  Cancer Res       Date:  2010-09-22       Impact factor: 12.701

2.  Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells.

Authors:  Yan Yang; Zehua Wang; Minfang Li; Shi Lu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

Review 3.  Aiming to immune elimination of ovarian cancer stem cells.

Authors:  Jiabo Di; Tjitske Duiveman-de Boer; Carl G Figdor; Ruurd Torensma
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

4.  A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines.

Authors:  Jessica Castro; Marc Ribó; Teresa Puig; Ramon Colomer; Maria Vilanova; Antoni Benito
Journal:  Invest New Drugs       Date:  2011-02-01       Impact factor: 3.850

5.  Atypical cell populations associated with acquired resistance to cytostatics and cancer stem cell features: the role of mitochondria in nuclear encapsulation.

Authors:  David Díaz-Carballo; Sebastian Gustmann; Holger Jastrow; Ali Haydar Acikelli; Philip Dammann; Jacqueline Klein; Ulrike Dembinski; Walter Bardenheuer; Sascha Malak; Marcos J Araúzo-Bravo; Beate Schultheis; Constanze Aldinger; Dirk Strumberg
Journal:  DNA Cell Biol       Date:  2014-08-15       Impact factor: 3.311

6.  Live-cell assays reveal selectivity and sensitivity of the multidrug response in budding yeast.

Authors:  Elena Vanacloig-Pedros; Carlos Lozano-Pérez; Benito Alarcón; Amparo Pascual-Ahuir; Markus Proft
Journal:  J Biol Chem       Date:  2019-07-11       Impact factor: 5.157

7.  Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.

Authors:  Ning Ji; Yuqi Yang; Chao-Yun Cai; Zi-Ning Lei; Jing-Quan Wang; Pranav Gupta; Suneet Shukla; Suresh V Ambudkar; Dexin Kong; Zhe-Sheng Chen
Journal:  Cancer Lett       Date:  2018-10-10       Impact factor: 8.679

Review 8.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

9.  The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy.

Authors:  Olga A Patutina; Nadezda L Mironova; Nelly A Popova; Vasily I Kaledin; Valery P Nikolin; Valentin V Vlassov; Marina A Zenkova
Journal:  BMC Cancer       Date:  2010-05-14       Impact factor: 4.430

10.  Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2.

Authors:  Ying-Ju Chen; Shiuan-Yin Chen; Ronald Lovel; Yi-Chu Ku; Yi-Hui Lai; Chiao-Ling Hung; Yu-Fen Li; Yin-Che Lu; Chien-Kuo Tai
Journal:  Oncol Lett       Date:  2016-07-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.